The content is available as a PDF (266.6 KB).
editorial . 2020 Jul 31:ciaa1133. doi: 10.1093/cid/ciaa1133
To Toci or Not to Toci for COVID-19: Is That Still the Question?
Guang-Shing Cheng
1,3, Joshua A Hill
2,3,4,✉
Guang-Shing Cheng
1
Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA
3
Clinical Research Division and Vaccine and Infectious Disease Division Center, Seattle, WA
Find articles by Guang-Shing Cheng
Joshua A Hill
2
Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
3
Clinical Research Division and Vaccine and Infectious Disease Division Center, Seattle, WA
4
Fred Hutchinson Cancer Research Center, Seattle, WA
Find articles by Joshua A Hill
1
Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA
2
Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA
3
Clinical Research Division and Vaccine and Infectious Disease Division Center, Seattle, WA
4
Fred Hutchinson Cancer Research Center, Seattle, WA
✉
Corresponding Author: Joshua A. Hill, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop E-400, Seattle, WA 98109, Tele: 206-667-6504, e-mail: jahill3@fredhutch.org
Received 2020 Jul 27.
Keywords: COVID, COVID-19, tocilizumab, immunomodulatory, SARS-CoV-2, coronavirus
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC7454367 PMID: 32735642
See "Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19" in volume 73 on page e445.
See commentary "Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19" in volume 73 on page e445.